Parexel Presents Real-World Safety Data on Trastuzumab Deruxtecan at ASCO 2026
核心洞察
Parexel presents two virtual research posters at ASCO (搜索) 2026, including real-world pulmonary safety analysis of trastuzumab deruxtecan in HER2-positive metastatic breast cancer (搜索) patients.
The company's oncology experience spans over 560 clinical studies involving more than 104,000 patients across 26,000 sites in 50+ countries over the past five years.
Parexel Biotech has delivered data supporting six FDA and three EMA new solid-tumor oncology drug approvals during this period.
Parexel, a leading global clinical development partner, announced the acceptance of two virtual research posters for presentation at the 2026 American Society of Clinical Oncology (ASCO (搜索)) Annual Meeting, taking place May 29-June 2 in Chicago. The research addresses critical challenges in oncology drug development and examines real-world safety outcomes for HER2 (搜索)-targeted therapy.
Research Focus on Trastuzumab Deruxtecan Safety
One of the key presentations focuses on the real-world pulmonary safety profile of trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer (搜索). The virtual poster, titled "Real-World Risk of Interstitial Lung Disease (搜索) and Pneumonitis (搜索) with Trastuzumab Deruxtecan vs Trastuzumab in HER2-Positive Metastatic Breast Cancer: A Propensity Score-Matched Analysis," provides critical safety data for this HER2 (搜索)-targeted therapy.
The second poster examines "Deficiencies in oncology marketing applications leading to FDA rejections: An assessment of complete response letters," analyzing common deficiencies that result in regulatory rejections.
Extensive Oncology Experience
Parexel's oncology portfolio demonstrates significant scale and impact. Over the past five years, the company's oncology experience spans more than 560 clinical studies, involving more than 104,000 patients across more than 26,000 sites in more than 50 countries. During this same period, Parexel Biotech delivered data supporting six U.S. Food and Drug Administration (FDA) and three European Medicines Agency (EMA) new solid-tumor oncology drug approvals.
"ASCO (搜索) is where the oncology community comes together to advance science that matters for patients, and Parexel's presence reflects that same commitment," said Jozsef Palatka, M.D., Senior Vice President and Global Therapeutic Head of Oncology at Parexel. "The research we are presenting exemplifies the rigor we bring to every program. Translating real-world evidence into confident clinical development decisions is how we help sponsors advance therapies forward for the patients who need them."
Patient-Centered Campaign Launch
Alongside the research presentations, Parexel unveiled "From Insights to Life," a new patient-focused creative campaign. The initiative centers on real people representing different disease states and demographics, navigating the space between medical diagnosis and daily living.
"What patients want most is to feel genuinely seen by the people working on their behalf, recognized for the full life they are striving to return to," said Stacy Hurt, Chief Patient Officer at Parexel. "At Parexel, truly listening to patients is the principle that guides every decision we make, every trial we design and every partnership we form."
The campaign builds on Parexel's award-winning Insights Generation Engine campaign, which received PR Week's 2026 Corporate Healthcare Campaign Award. The new initiative will roll out throughout 2026 across Parexel's digital platforms and at major biopharmaceutical industry events, including the American Diabetes Association and the World Orphan Drug Congress.
Leadership Presence at ASCO
Dr. Palatka will lead Parexel's on-site activities at the meeting, joined by Charlotte Moser, Chief Medical Officer; Jim Anthony, Chief Commercial Officer and President of Parexel Biotech; Stacy Hurt, Chief Patient Officer; Mike D'Ambrosio, Senior Vice President and Global Head of Real World Research; and members of Parexel's medical, commercial and marketing teams.